Tiny startup could be the next $52 billion megatitan

One small trigger could stop Big Pharma dead in its tracks

You are receiving this as part of your free subscription to Money Morning Profit Alerts. To remove your email from this list, unsubscribe here.

Wall Street's Rat Race: Don't Fall into Big Pharma's Trap (Click to watch...) Dear Profit Alerts Member, This tiny startup is in position to disrupt a trillion-dollar industry... The pharmaceutical industry. All of this comes as a result of one groundbreaking discovery in modern medicine... One that could hold the key to nearly every incurable disease known to man. It could stop Big Pharma dead in its tracks... It could reorganize all of Wall Street's investing arena... It could even have YOU living rich beyond your WILDEST dreams. Just how wild? I'm talking about up to a 54,000% revenue surge that could hit in the blink of an eye. But this isn't one of those private deals reserved for high-net-worth investors only... You don't need to be a millionaire or an accredited investor. In fact, anyone can take part with the chump change they have lying around. Your shot at making hundreds of thousands, if not millions of dollars, from a single deal - starts right here. There's a reason this is being hailed as "the holy grail." Go here, and I'll show you why. Sincerely, Mike Ward Co-Founder, National Institute for Cannabis Investors To unsubscribe from Money Morning Profit Alerts emails click here. © 2019 Money Morning All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any recommendations in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 1125 N Charles Street, Baltimore MD 21201. To read our privacy policy click here. To contact Customer Service click here.